Video #2: U.S.-Canadian cross-border IPOs

In the second video of our IPO essentials series, Robbie Leibel and Chris Bornhorst of our Capital Markets group explore a number of key items to keep in mind for companies looking to complete a cross-border IPO in Canada and the United States, including:

  • general processes and the time it takes to complete a cross-border IPO;
  • engaging in publicity;
  • prospectus and regulatory review;
  • financial statement requirements; and
  • testing the waters before publicly announcing an IPO.

Click here to visit the main IPO series page.


Robbie Leibel (00:10): Hi everyone. My name is Robbie Leibel and I'm a Partner in the Securities Group at Torys in Toronto. Today, I'm joined by my colleague, Chris Bornhorst, a Partner in our Securities Group in New York. We'd like to welcome you to the second installment of our IPO webinar series. In the first video of the series, our colleagues discuss some key gating items that companies will need to be mindful of at the beginning of the IPO process in order to become IPO-ready. In today's installment, Chris and I will highlight a number of key items to keep in mind for companies looking to complete a cross-border IPO in Canada and the United States.

Chris Bornhorst (00:44): Given the similarity between Canadian and US securities laws, there's quite a bit of overlap. So our goal here today is to focus on the important differences and considerations involved when there is a potential to be regulated in both jurisdictions.

Robbie Leibel (00:57): Earlier in the webinar series, we discussed the key steps and work streams for a Canadian-only IPO. To recap, a Canadian IPO typically takes about four to six months to complete assuming favorable market conditions and no significant regulatory issues. This includes the time necessary to prepare financial statements for prospectus disclosure, complete due diligence, go through regulatory review, marketing the IPO, and then pricing and closing the offering.

Chris Bornhorst (01:23): If a company is looking to complete a cross-border IPO in the United States, with the US Stock Exchange listing, for example, on the New York Stock Exchange or NASDAQ, much of the same work for a Canadian IPO can be applied towards the US IPO and the process can be made streamlined and efficient. Potentially a cross-border IPO can be completed in the same timeframe as a Canadian-only IPO. However, it's important to consider some of the legal considerations that arise in the US, as well as in Canada, in order to ensure a smooth process. One issue I'd like to start off with, because it is relevant early on in the process, is what to do about publicity. For example, the company's press releases and website content once the company has kicked off an IPO process. Any information the company makes available to the public has the potential to be deemed offer material under US securities laws. Thankfully, there are some exceptions. For example, ordinary course trade press that is not targeted directly at investors and communications made more than 30 days prior to the public filing of the SEC registration statement. For these reasons, companies seeking to kick off an IPO should consult with counsel regarding the press releases, IR and website content early on in the process.

Robbie Leibel (02:35): That's a great point, Chris, and it's not too dissimilar from the general advice we'd be giving our Canadian clients who may be looking to complete an IPO in the near term. That is, to generally avoid public statements and public disclosures outside of the ordinary course of business as you're gearing up to launch an IPO. Chris, why don't you speak now a bit about the key differences between US and Canada as it relates to preparing and settling the primary disclosure document for an IPO, being a "prospectus" as it's referred to in Canada, and a "registration statement" as it's referred to in the United States?

Chris Bornhorst (03:06): Sure. The US and Canadian forms contain many of the same disclosure requirements. For example, financial statements, MD&A, description of the business, executive compensation and risk factors. And as a result, the prospectus ultimately will be substantially the same in both jurisdictions. One complication, however, is that the prospectus is subject to review by two sets of regulators: one in Canada and the SEC in the United States. And these regulators operate according to different timelines and procedures. The SEC, for example, takes 30 days to issue their initial comment letter, as compared to 10 days in Canada. In addition, the SEC requires IPO companies to file a formal response letter to comments and file an amended registration statement along with it, although the SEC staff may take a more informal approach and closer to the IPO pricing. By contrast, the Canadian review process is a bit more casual with opportunities to have wide discussions with the regulator if needed, even early on in the process. Thankfully, companies are permitted in both jurisdictions to set up regulatory comments on a confidential basis before any prospectus or announcement about the IPO is made public.

Robbie Leibel (04:16): That's a good point. Now, turning to financial statement requirements, the general rule for IPOs in Canada is that you need three years of audited historical financial statements that have been audited in accordance with IFRS. In addition, IPO companies must include interim financial statements as well as any required financial statements for recent significant acquisitions.

Chris Bornhorst (04:37): Unlike in Canada, only two years of audited financial statements are required for most IPO companies in the US. However, in a cross-border IPO, issuers end up needing to file three years of financial statements because of the Canadian requirements. Another important consideration is to examine the significance of recent or probable acquisitions under the US rules, which differ from the Canadian rules and may increase the likelihood of needing to file financial statements for target companies as well as pro forma financials. One key difference between the Canadian and US rules is that the minimum significant threshold in the US is only 20% versus 30% in Canada. And only one of the three signficance tests—assets, income or investments—needs to be tripped in order to be deemed significant, versus two out of the three tests in Canada. Additionally, Canadian companies that are "foreign private issuers" under the US rules are permitted to file IFRS financial statements with the SEC registration statement. However, if they fail to qualify as a "foreign private issuer", then the company will need to include US GAAP financial statements. The "foreign private issuer" test, I should mention, is failed if more than 50% of Canadian company's shareholders are in the United States—what we call a "shareholder test"—and the company also fails the "business contacts" test. Now the "business contacts" test is failed if any of the following are true: (1) the company is headquartered or administered in the United States; (2) more than half of its directors are US citizens or residents; (3) more than half of its executive officers are US citizens or residents; and (4) more than 50% of its assets are in the United States. The "foreign private issuer" test is important for companies to consider early on in the process, as it has a lot of consequences under US securities laws, not the least of which is the requirement for US GAAP financial statements.

Robbie Leibel (06:25): That's right. And in this situation, the Canadian regulators will permit you to prepare your financial statements in accordance with US GAAP. However, recently, given the way that the technical rules are drafted, the Canadian regulators have been requiring the issuers looking to do a cross-border IPO actually apply for exemptive relief in order to be able to audit their financial statements in accordance with the US GAAP. This has become a fairly standard form of relief and should not be an issue to obtain. However, issuers should be mindful of this requirement as fairly to apply for the relief could lead to delays to your timeline.

Chris Bornhorst (07:02): Either way, whether IFRS or US GAAP, the financial statements for a cross-border IPO must be audited under US auditing standards by an auditor that is registered with the US Public Company Accounting Oversight Board, or the PCAOB. Canadian companies should confirm that their Canadian audit partner is in communication with their US counterparts very early on in the process to ensure that the US audit is completed, which may take several months. Also, a Canadian company completing a US IPO must ensure that its auditors are independent under US rules, as this analysis may differ between the US and Canada.

Robbie Leibel (07:37): Turning to marketing for a second, you know, issuers looking to do a cross-border IPO will also need to be mindful of the different timing requirements under various securities law regimes on both sides of the border. And an example of this really does relate to marketing of the IPO to potential investors. In both Canada and the US, issuers have the ability to confidentially "test the waters" before publicly announcing an IPO in order to see if there's sufficient interest in the IPO. However, there's a cooling off period in Canada, where issuers are required to stop all Canadian "testing the waters" meetings and then wait an additional 15 days before the issuer can publicly file that preliminary prospectus.

Chris Bornhorst (08:18): There's no equivalent restriction in the US, and technically US "testing the waters" can continue all the way up until the roadshow. However, the US has a different "cooling off" period whereby an issuer is not permitted to commence the public roadshow until these 15 days after the first public filing of the SEC registration statement. As such, issuers and underwriters will want to give some consideration to organizing their "testing the waters" and roadshow schedules on both sides of the border in order to be able to maximize the number of days that they're able to be out marketing the IPO, while still complying with the various "cooling off" periods under Canadian and US rules.

Robbie Leibel (08:55): And usually issuers will wait until they and the underwriters are reasonably certain that the IPO will actually proceed before filing that prospectus publicly. Because once that public filing has been made, it can't be taken back down. Another important factor that comes up from time to time in assessing where to IPO relates to where your existing shareholders reside. For example, if you have a number of Canadian pre-IPO shareholders, unless you were to file a prospectus in Canada, those pre-IPO Canadian shareholders will have permanently restricted stock. That stock will never become freely tradable until a prospectus has been filed in Canada. So in cases where a Canadian company is looking to do a US IPO, and has a number of existing Canadian shareholders, it has become fairly commonplace for the company to also file a prospectus in Canada, even if it's just a "non-offering" prospectus, in order to ensure that their existing Canadian shareholders will have freely tradable stock on closing of the IPO.

Chris Bornhorst (09:55): This is a good point, and a similar but related issue arises under US securities laws. If a Canadian company is looking to only do a Canadian IPO, it may actually need to register with the SEC if the company is not considered a "foreign private issuer", because otherwise the shares issued in Canada would be restricted from resale back into the United States for a period of one year. This is an issue that we sometimes refer to as "flow back". In the event the "foreign private issuer" test has failed, it is technically possible to complete a Canadian-owning IPO without SEC registration, but it becomes practically very challenging to manage because brokers will need to notify their customer accounts of the one year "flow back" restriction. The TSX, for example, would give the stock a ".s" designation for "Regulation S", which is the applicable US regulation in order to help enforce this. As such, many Canadian companies that are not "foreign private issuers" end up needing to register with the SEC to avoid a ".s" designation. This does not mean, however, that the company needs to be listed on a US stock exchange, but it does require the filing of an SEC registration that is subject to review and comment by the SEC.

Robbie Leibel (11:02): Thanks, Chris. I think that's probably a good place for us to pause. I mean, it's obviously quite challenging to summarize the multitude of considerations involved in deciding on which jurisdictions to take your company public. But we hope that this segment has at least put some of the key issues on your radar as you are considering the ideal markets for your IPO. We thank you for taking the time to listen to our segment today. Stay tuned for the next installment of our IPO webinar series coming very soon.

Chris Bornhorst (11:28): Thanks, everyone.

Robbie Leibel (11:29): Thanks.

Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.

Développement de contre-mesures médicales au Canada

Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.

Exploiter les voies réglementaires mises en place lors de la pandémie de COVID-19

Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.

Le rôle de la Stratégie dans le renforcement du régime réglementaire de la santé au Canada

La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.

Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.

Prochaines étapes

Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.

Inscrivez-vous pour recevoir les dernières nouvelles

Restez à l’affût des nouvelles d’intérêt, des commentaires, des mises à jour et des publications de Torys.

Inscrivez-vous maintenant